This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Buy Clorox (CLX) Stock Now for Coronavirus Volatility and Beyond?
by Benjamin Rains
Clorox shares have surged 35% in 2020 to crush the S&P 500's 5% decline as its disinfectant wipes fly off the shelves during the coronavirus pandemic. With this in mind, investors might want to consider buying CLX stock as coronavirus volatility returns...
Is Clorox (CLX) Stock Still a Great Buy for the Eventual Coronavirus Recovery?
by Benjamin Rains
Clorox topped our quarterly earnings and revenue estimates on May 1, and the stock has jumped 12% since the end of April. Some investors might think the rally is overdone. But is Clorox still a great buy even near its new highs?
3 Highly-Ranked Stocks to Buy for the Coronavirus Economy & the Eventual Recovery
by Benjamin Rains
On today's episode of Full Court Finance, we explore three stocks that appear to be buys at the moment and down the road when the economy eventually turns around from the coronavirus downturn...
Why Clorox (CLX) Stock is a Long-Term Buy Far Beyond the Coronavirus
by Benjamin Rains
Clorox sells disinfectant products that kill germs at home and in healthcare settings, which makes it almost tailor-made for the coronavirus economy. Better still, Clorox's portfolio is far more diverse and CLX appears to be a solid longer-term buy...
Ecolab's (ECL) Gallay Medical Buyout to Boost Healthcare Arm
by Zacks Equity Research
The addition of Gallay Medical is likely to boost Ecolab's (ECL) Healthcare offerings.
Ecolab's Chemstar Buyout to Boost Food & Beverage Business
by Zacks Equity Research
Chemstar's flagship Sterilox Fresh to help boost Ecolab's (ECL) Food & Beverage unit.
Soap & Cleaning Materials Industry Outlook Upbeat on New Products
by Rajani Lohia
The FMCG space is likely to gain from investment in brands, innovation, cost-containment and pricing actions. However, its struggles against higher raw material and transportation costs continue.
Estee Lauder (EL) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Estee Lauder (EL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Procter & Gamble Moves Up the Charts: Will Growth Continue?
by Zacks Equity Research
Procter & Gamble (PG) emphasizes on improving its product portfolio through strategic initiatives. Also, the company is on track with its cost-saving plans.
5 Top European Stocks to Buy on ECB's Hints of More Stimulus
by Sanghamitra Saha
The ECB hints at more policy stimulus, making the conditions favorable for these stocks.